ArticleFrontiers in veterinary science2022
Predicting cross-protection against foot-and-mouth disease virus strains by serology after vaccination.
Article in Frontiers in veterinary science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Evaluation of Antigen Productivity and Inactivation Kinetics of a Recombinant Foot-and-Mouth Disease SAT1 Vaccine Strain.Viruses · 2026Article
- Article
- Evolutionary and structural insights into VP1 epitopes of representative SAT-type FMDV strains: implications for candidate vaccine selection.Veterinary research · 2025Review
- Opportunities for machine learning to predict cross-neutralization in FMDV serotype O.PLoS computational biology · 2025Article
- Article
- An antigen panel to assess the regional relevance of foot and mouth disease vaccines.NPJ vaccines · 2025Article
- Immunogenicity of a foot-and-mouth disease (FMD) vaccine against serotypes O, A, SAT-2, and Asia-1 in the Middle East and many parts of Africa, Southeast Asia and Europe.Virology journal · 2025Article
- Duration of the antibody response following intradermal administration of a quarter-dose oil adjuvant foot-and-mouth disease vaccine in sheep.Veterinary research communications · 2025Article
- Eastern Africa Origin of SAT2 Topotype XIV Foot-and-Mouth Disease Virus Outbreaks, Western Asia, 2023.Emerging infectious diseases · 2025Article
- Preliminary evaluation of a novel serotype O foot-and-mouth disease mRNA vaccine.Frontiers in microbiology · 2025Article
- Article
- Review
- Calcium Chloride as a Novel Stabilizer for Foot-and-Mouth Disease Virus and Its Application in the Vaccine Formulation.Vaccines · 2024Article
- Evaluation of a Vaccine Candidate Designed for Broad-Spectrum Protection against Type A Foot-and-Mouth Disease in Asia.Vaccines · 2024Article
- Defining correlates of protection for mammalian livestock vaccines against high-priority viral diseases.Frontiers in immunology · 2024Review
- Article
- Article
- The Immunogenicity of a Foot-and-Mouth Disease Virus Serotype O Vaccine in Commercial and Subsistence Cattle Herds in Zambia.Vaccines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serology is widely used to predict whether vaccinated individuals and populations will be protected against infectious diseases, including foot-and-mouth disease (FMD), which affects cloven-hoofed animals. Neutralising antibody titres to FMD challenge viruses correlate to protection against FMD, for vaccinated cattle that are infected with the same strain as in the vaccine (homologous protection). Similar relationships exist for cross-strain protection between different vaccine and challenge viruses, although much less data are available for these heterologous studies. Poor inter-laboratory reproducibility of the virus neutralisation test (VNT) also hampers comparisons between studies. Therefore, day-of-challenge sera (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.